Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis

Anita Moein¹ | Tong Lu¹ | Siv Jönsson² | Jakob Ribbing² | Nastya Kassir¹
Wenhui Zhang¹ | Gizette Sperinde¹ | Rong Zhang¹ | Meina Tang¹
Young S. Oh¹ | Rene Bruno³ | Rui Zhu¹

¹Genentech, Inc., South San Francisco, California, USA
²Pharmetheus AB, Uppsala, Sweden
³Genentech/Roche, Marseille, France

Correspondence
Rui Zhu, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA.
Email: zhu.rui@gene.com

Funding information
Genentech Inc

Abstract
Etrolizumab is an IgG1-humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately-to-severely active ulcerative colitis (UC). Population pharmacokinetic (PK) analysis was performed to characterize etrolizumab PK properties in patients with moderately-to-severely active UC and evaluate covariate impacts on exposure. The population PK model was developed based on etrolizumab serum concentrations from patients with moderately-to-severely active UC enrolled in six studies (one phase I, one phase II, and four phase III) and validated using another phase III clinical trial. Stepwise covariate modeling was used to evaluate the impact of 23 prespecified covariates. Etrolizumab PK was best described by a two-compartment model with first-order absorption, with clearance decreasing over time. Population typical values were 0.260 L/day for clearance (CL) during the first dosing internal, 2.61 L for central volume, 71.2% for bioavailability, and 0.193/day for absorption rate. CL reduced over the study duration, the typical maximum reduction was 26% with an onset half-life of 4.8 weeks. Consequently, the predicted mean terminal half-life was shorter after a single dose (13.0 days) compared to that at steady-state (17.1 days). Baseline body weight and albumin were the most impactful covariates for etrolizumab exposure. Final population PK model well characterized the PK properties of etrolizumab in patients with moderately-to-severely active UC and identified influential covariate effects.

Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
Etrolizumab is an IgG1-humanized monoclonal antibody that specifically targets the β7 subunit of α4β7 and α4Eβ7 integrins, and it has been evaluated for the treatment of moderately-to-severely active ulcerative colitis (UC).
ETROLIZUMAB POPULATION PK IN UC

WHAT QUESTION DID THIS STUDY ADDRESS?
The population pharmacokinetics (PK) model well-characterized the PK properties of etrolizumab in patients with moderately-to-severely active UC and identified influential covariate effects.

WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
Etrolizumab PK was best described by a two-compartment model with first-order absorption, with clearance decreasing over time. Baseline body weight and albumin were the most impactful covariates for etrolizumab exposure.

HOW MIGHT THIS CHANGE DRUG DISCOVERY, DEVELOPMENT, AND/OR THERAPEUTICS?
This model can be used to derive individual predictions of etrolizumab PK for exposure-response analysis to inform etrolizumab dose optimization in patients with UC.

INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel disease that affects the colon in various patterns. UC symptoms include mucosal inflammation and ulcers, rectal bleeding, diarrhea, and abdominal pain; it may cause severe bloody diarrhea and toxic megacolon leading to surgery. Dysregulation of the mucosal immune system in response to environmental factors, such as commensal microbiota, plays an important role in the pathogenesis of UC. Patients with moderately-to-severely active UC currently treated with corticosteroids, immunosuppressants, or targeted therapies, such as tumor necrosis factor (anti-TNF) inhibitors, vedolizumab, tofacitinib, ozanimod, and ustekinumab. However, even with these different therapy options, there are still a large number of patients not maintaining a durable treatment response.

Etrolizumab is an IgG1-humanized monoclonal antibody that specifically targets the β7 subunit of both the α4β7 and α4Eβ7 integrins, which regulate trafficking and retention of leukocyte/lymphocyte subsets, respectively, in the intestinal mucosa. Etrolizumab does not bind to α4β1, which regulates trafficking to both mucosal and non-mucosal tissues (including the central nervous system), and therefore represents a novel gut mucosal-selective anti-trafficking agent.

The objectives of this study were to develop and validate a population pharmacokinetic (PK) model for etrolizumab in patients with UC using data from seven clinical studies spanning phase I, II, and III. The population PK model aimed to characterize the PK properties of etrolizumab and to assess the impact of potential clinically relevant intrinsic and extrinsic covariates on etrolizumab PK. The final population PK model predicted etrolizumab exposures for individual patients, which were used to characterize the exposure–response relationship in a sequential analysis.

METHODS

Clinical trials
For this study, we used ABS4262g (phase I; NCT00694980), EUCALYPTUS (NCT01336465), HIBISCUS I/HIBISCUS II (NCT02163759/NCT02171429), HICKORY (NCT02100696), LAUREL (NCT02165215), and GARDENIA (NCT02136069) clinical trials. All clinical trial information can be accessed through the following website: https://clinicaltrials.gov/.

Data and study design
A total of seven studies (1 phase I, 1 phase II, and 5 phase III) were used in the population PK development (6 studies) and external validation (1 study). A listing of the studies and key study information, including population, dosing regimen, and number of subjects treated with etrolizumab is provided in Table 1. The PK assay and antidrug antibody (ADA) immunoassay were reported previously for phase I-II and III studies. All studies were approved by the institutional review board or independent ethics committee and were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines.

Population PK model development and covariate analysis
The population PK analysis was performed using NONMEM version 7.3.0 (ICON Development Solutions), with the first-order conditional estimation (FOCE) and the INTERACTION option. Nonlinear mixed effects models were used to fit the concentration–time data of etrolizumab. Absolute bioavailability (F), clearance (CL), and volume of distribution (V) parameters were
estimated since data included both i.v. and s.c. administration. Based on the graphical exploratory analysis, models took into account time-dependency in CL (Figure S1).

Interindividual variability (IIV) in PK parameters were modeled as exponential random-effect models in order to constrain the individual parameter values positively, which were thus assumed to follow a log-normal distribution. IIVs were modeled as normally distributed on the logit-transformed scale to constrain values between zero and one for certain parameters (e.g., F). The residual error model was a combined additive and proportional error model (no transformation).

The covariate model was developed based on prespecified mechanistic, structural, and exploratory covariates (Table 2). Mechanistic covariates (i.e., body weight on CL and V parameters) were included in the base model based on mechanistic understanding, therefore no statistical evaluation for inclusion was performed. Body weight was chosen to represent changes in etrolizumab PK as a function of body size and was described using an allometric model with a reference weight of 70 kg.21,22

The structural and exploratory covariates were evaluated using stepwise covariate model building procedure in two subsequent phases.23 The structural covariates pre-assigned to evaluate were part of the design of the studies or anticipated to be major predictors explaining variability and were tested and retained in the model based on statistical significance ($p < 0.05$ forward and $p < 0.01$ backward) and biologically reasonable parameter estimates. The exploratory covariates were evaluated and retained in the model based on statistical significance (with more stringent criteria: $p < 0.0001$) and biologically reasonable parameter estimates. For estimation of covariate coefficients, the baseline/screening value of the covariate was used, except for ADA, which was explored as time-varying, hence the actual value of the ADA covariate at the time of the observation was used and imputed if missing (imputed as negative ADA for missing baseline measurements; for missing postdose measurements, imputed by carrying forward the previous postdose ADA measurement, and, if not possible, the next ADA measurement was carried backward; if all postdose ADA observations were missing, the measurements were imputed as ADA negative). Time-varying ADA status (positive or negative) was evaluated first, if significant, time-varying ADA titers were further evaluated in place of the ADA status. Continuous covariates (e.g., albumin, C-reactive protein [CRP], fecal calprotectin [FeCal], and age) were implemented as exponential models, and categorical covariates (e.g., prior TNF-α antagonist therapy status, and concomitant therapy use) were entered as a fractional change in parameter value, in relation to the most common category.

The impact of covariate-parameter relationships on week-4 trough concentration based on the final population PK model was assessed in a forest plot; the uncertainty was illustrated as the 95% confidence interval (CI),

**Table 1** Summary of etrolizumab studies included in population PK model development and external evaluation

| Study                        | Phase | Number of subjects | Number of PK observations | Population         | Dose regimen                                                                 |
|------------------------------|-------|--------------------|---------------------------|--------------------|------------------------------------------------------------------------------|
| Model development data set   |       |                    |                           |                    |                                                                              |
| ABS4262g                     | I     | 38                 | 537                       | UC (TNF Naïve and TNF IR) | SAD: 0.3, 1, 3, 10 mg/kg i.v.; 1 mg/kg, 3 mg/kg s.c.                           |
|                              |       |                    |                           |                    | MAD: 0.5, 1.5, 3 mg/kg s.c. Q4W until week 8; 4 mg/kg i.v. Q4W until week 8  |
| EUCALYPTUS                   | II    | 81                 | 609                       | UC (TNF Naïve and TNF IR) | 105 mg SC Q4W until week 8; 420 mg s.c. week 0, 315 mg s.c. weeks 2, 4, and 8 |
| HIBISCUS I/HIBISCUS II       | III   | 285                | 608                       | UC (TNF Naïve)     | 105 mg s.c. Q4W                                                              |
| HICKORY                      | III   | 509                | 1284                      | UC (TNF IR)        | 105 mg s.c. Q4W                                                              |
| LAUREL                       | III   | 350                | 914                       | UC (TNF Naïve)     | 105 mg s.c. Q4W                                                              |
| External validation data set |       |                    |                           |                    |                                                                              |
| GARDENIA                     | III   | 184                | 742                       | UC (TNF Naïve)     | 105 mg s.c. Q4W                                                              |
| All                          |       | 1447               | 4694                      |                    |                                                                              |

Note: Intravenous infusion over 1 hour in i.v. cohorts.

Abbreviations: i.v., intravenous; MAD, multiple ascending dose; PK, pharmacokinetic; Q4W, every 4 weeks; SAD, single ascending dose; s.c., subcutaneous; TNF IR, patients with inadequate response or intolerance to prior anti-TNF treatment; TNF Naïve, patients without prior anti-TNF treatment; TNF, anti-tumor necrosis factor treatment; UC, ulcerative colitis.

*a* No PK observations were obtained following 1 mg/kg s.c. in the phase I ABS4262g study.
ETROLIZUMAB POPULATION PK IN UC

based on the NONMEM covariance matrix. Reference patient’s baseline values in the forest plot were assigned based on median values for continuous covariates or the most common category for categorical covariates.

**Model evaluation and external validation**

Model evaluation was based on the inspection of graphical diagnostics, including goodness of fit plots and prediction-corrected visual predictive checks (pcVPC), as well as changes in the objective function value provided by NONMEM, relative standard errors (RSE) and plausibility of the parameter estimate. In addition, external validation was performed using GARDENIA data.

**RESULTS**

**Final population PK model**

The final population PK analysis dataset included a total of 4694 PK observations from 1447 patients with moderately-to-severely active UC. The baseline demographic summaries and the observed PK profiles of the seven studies are presented in Table 3 and Figure S2.

The population PK parameter estimates of the final etrolizumab PK model are presented in Table 4. The final population PK model was a two-compartment model with first-order absorption, and CL decreasing with time according to an exponential function (Equation 1), stepping down after each subsequent dose.

\[
CL_{TSFD,j} = CL_{TSFD=0} \cdot \left(1 - \text{Maxred} \cdot \left(1 - e^{-\log(2)/\text{Onset}} \cdot \left(TSFD_j - \text{TAD}_j\right)\right)\right)
\]  

where TSFD is the time since first dose (in days), Maxred is the maximum reduction in CL over time, Onset is the half-life (in weeks) for the time-dependent change in CL (multiply by 7 to convert the Onset unit from weeks to days), and TAD is time after the most recent dose (in days).

IIV terms were included on F, central volume of distribution (\(V_c\)), peripheral volume of distribution (\(V_p\)), CL, and Maxred. The IIVs were log-normally distributed, apart for F and Maxred, where IIVs were normally distributed on the logit-transformed parameters to constrain values between zero and one. The residual variability for etrolizumab was described by a combined additive and proportional error model. The magnitude of the residual error variability was 19% lower in phase I/II studies compared to phase III studies, meaning that observations collected in phase III studies had larger unexplained variability.

Population typical value were estimated as 0.260 L/day for CL during the first dosing interval, 2.61 L for \(V_c\), 71.2% for \(Q\), 3.0 L for \(V_p\), and 0.260 L/day for CL during the first dosing interval. The residual error variability was 19% lower in phase I/II studies compared to phase III studies, meaning that observations collected in phase III studies had larger unexplained variability.
for F, and 0.193/day for absorption rate of the s.c. formulation (IIV coefficient of variation: CL 24.3%, Vc 25.2%, and F 21.1%). CL declined over study duration, eventually reaching a maximum reduction of 26% with onset half-life of 4.8 weeks, starting at administration of the second dose (i.e., after 4 weeks lag time, for Q4W multiple dosing). The illustration of typical CL versus TSFD for the empirical time-varying model is shown in Figure S3. The typical terminal half-lives after a single dose and at steady-state (95% CI) derived from the population PK parameters were 13.0 (12.2–13.9) and 17.1 (16.1–18.3) days, respectively.

In the final model, all PK parameters estimated with relatively good precision (RSE). Shrinkage was 20%–28% for residual error and CL, however, it was substantially higher for IIV on other parameters. Therefore, eta diagnostics (e.g., displaying etas vs. covariates), were interpreted with caution.

### Covariate analysis

The CL of etrolizumab was dependent on baseline body weight, albumin, CRP, prior anti-TNF status, disease extension (left-side colitis, extensive/pancolitis, and other disease extension), and time-varying ADA titer (Table 4). The exponent for the effect of weight on CL (0.872) suggests a higher CL of etrolizumab in heavier subjects. On
the other hand, subjects with high albumin levels tend to have lower CL (relative change of −3.1% per 1 g/L albumin increase). In addition, CL increased with increasing CRP (relative change of 0.46% per 1 mg/L CRP increase), was 4.9% higher in patients that had been on prior anti-TNF therapy, was 8.2% higher in patients with extensive disease/pancolitis and 18% higher in patients with other extension (both categories vs. left-sided colitis) and increased with increasing ADA titer (relative change of 3.7% per titer unit). The inter-compartmental clearance (Q) and volumes (Vc and Vp) of etrolizumab were dependent on baseline body weight. The exponents for the effect of weight on Q (0.872) and on Vc and Vp (0.788) suggest higher Q, Vc, and Vp of etrolizumab in heavier subjects.

| Table 4 Parameter estimates of the final pharmacokinetic model | Parameter | Unit | Value | RSE (%) | SHR (%) |
| --- | --- | --- | --- | --- | --- |
| CL | L/day | 0.260 | 7.12 |
| Vc | L | 2.61 | 5.82 |
| Q | L/day | 0.449 | 12.9 |
| Vp | L | 1.77 | 10.8 |
| F | | 0.712 | 7.35 |
| ka | 1/day | 0.193 | 11.2 |
| Maxred | Relative decline | 0.263 | 6.70 |
| Onset | weeks | 4.81 | 12.7 |

Body weight on clearance parameters:

- 0.872

Body weight on volume parameters:

- 0.788

Albumin on CL:

- −0.0314

CRP on CL:

- 0.00458

Prior TNF on CL:

- 0.0490

Extensive/pancolitis on CL:

- 0.0816

Other disease extension on CL:

- 0.181

Phase I and II studies on residual error:

- −0.192

ADAT on CL:

- 0.0365

IIV CL CV:

- 0.243

IIV Vc CV:

- 0.262

IIV F SD:

- 0.733

IIV Maxred SD:

- 0.597

Proportional residual error:

- 0.196

Additive residual error SD, μg/ml:

- 0.427

**Abbreviations:** ADAT, anti-drug antibody titer; CL, clearance; CRP, C-reactive protein; CV, coefficient of variation; F, bioavailability; IIV, interindividual variability; ka, first-order absorption rate constant; OFV, objective function value; Maxred, maximum reduction in clearance over time; Onset, half-life for the time-dependent change in CL; Q, inter-compartmental clearance; RSE, relative standard error; SD, standard deviation; SE, standard error; SHR, shrinkage; TAD, time after most recent dose; TSFD, time since first dose; Vc, central volume of distribution; Vp, peripheral volume of distribution.

*a* The estimate is θ for parameters (P) CL and Q in TVP = P_population ⋅ (WT / 70) ^ θ.  
*The estimate is θ for parameters (P) Vc and Vp in TVP = P_population ⋅ (WT / 70) ^ θ.  
*CL_TSFD, j = CL_TSFD, 0 ⋅ (1 − Maxred ⋅ (1 − e ^ (−log(2) Onset ⋅ (TSFD, j − TAD)))).  
*The estimate for covariate m is θ in Cov_m = e ^ (θ(Cov_m − Cov_m,ref)).  
*The covariate effect is on the overall residual error (additive and proportional).  
*Relative change per unit albumin, CRP, and ADAT, respectively.  
*Relative change versus no prior TNF, versus left-sided colitis and versus phase III, respectively.  
*The IIV is presented as the SD on the logit scale. The corresponding CV for F and Maxred for the final model were 0.211 and 0.440, respectively. The CV was calculated using the following approximation: SD = θ ⋅ (1 − θ) ⋅ SD_pix and CV = SD / θ, where θ is the typical value for F and Maxred, respectively.
in the forest plot (Figure 1). Baseline body weight and albumin are the most impactful covariates for etrolizumab exposure.

**Final population PK model evaluation and external validation**

The model evaluation (pcVPC) of etrolizumab concentration versus TSFD, stratified by study, is presented in Figure 2. The observed concentrations were reasonably well-described by the model. The goodness-of-fit plots also showed that the predictions from the final model were generally consistent with the observed data (Figure S4).

The external evaluation of etrolizumab concentrations versus time, based on data from GARDENIA, validated the model (Figure 3) with the observed concentrations being reasonably well-described by the model (median as well as 80% prediction interval).

**DISCUSSION**

The concentration–time profiles of etrolizumab in patients with UC were adequately described by a two-compartment disposition model with first-order absorption, with clearance decreasing over time. Given that the clearance of etrolizumab decreases over time (Equation 1), the predicted mean terminal half-life was shorter after a single dose (13.0 days) compared to that at steady-state (17.1 days).

Baseline body weight, albumin, CRP, prior anti-TNF status, disease extension (left-side colitis, extensive/pancolitis, and other disease extension), and time-varying ADA titer were identified as statistically significant covariates of CL, whereas body weight was also identified as a statistically significant covariate of $V_c$, $V_p$, and Q. However, these covariates combined only accounted for a small portion of IIV for CL (21.4%) and $V_c$ (4.91%), indicating their impact on overall etrolizumab PK...
FIGURE 2  Prediction corrected visual predictive check of etrolizumab concentrations versus time since first dose, for the final population pharmacokinetic model, stratified by study. Etrolizumab concentrations are displayed versus time since first dose. The solid and dashed red lines represent the median, 10th and 90th percentiles of the observations; the shaded red and blue areas represent the 95% confidence interval (CI) of the median, 10th and 90th percentiles predicted by the model. The observed data are indicated by open circles.
exposure may be limited. As shown in Figure 1, baseline body weight and albumin are the most impactful covariates for etrolizumab exposure, and higher CRP was associated with lower exposure, whereas all other covariate effects are mild with the ratio over the reference subject within ±20%. Other disease extension appears to have a −20% impact on exposure (i.e., trough concentration at week 4), but it has large uncertainty due to limited patients in this group (2% of the data). The lower magnitude of the residual error variability found for the phase I and II data compared to phase III data is expected, because earlier phase clinical studies may be better controlled for both treatment adherence and timing of PK samples. Clinical studies phases (I/II vs. III) were also tested on CL and F, but it showed no effect on CL or bioavailability, meaning that manufacturing process and/or PK assay changes have minimal impact on etrolizumab PK.

The influence of the disease activity marker albumin on clearance (decreasing CL with increasing albumin) is in line with previous observations for monoclonal antibodies, for example, vedolizumab, a monoclonal antibody that targets $\alpha_4\beta_7$ integrin, and other monoclonal antibodies in this disease area, such as infliximab.\textsuperscript{26–28} The influence of the second disease activity marker identified, CRP (increasing CL with increasing CRP), has also been assessed for both vedolizumab and infliximab.\textsuperscript{26,28,29} Both albumin and CRP have been identified as a predictor for monoclonal antibody clearance in inflammatory disease.\textsuperscript{27,30} Furthermore, the increase in clearance due to occurrence of ADA, which
was estimated in the final population PK model using the ADA titer, is a well-known observation for monoclonal antibodies. However, the occurrence of ADA appeared to have a very mild effect for etrolizumab with 3.7% relative change in CL per unit ADA titer (Table 4), also illustrated in Figure 1 by the minimal impact on week-4 trough concentration compared to other statistically significant covariates. The finding of a slightly higher clearance in patients that had been on prior anti-TNF (4.9%) has been observed for vedolizumab (4% higher clearance).31 The effect of disease extension on CL may require further elucidation. Although patients with greater disease extent, such as extensive/pancolitis in phase III, had 8.2% increase in CL (compared to the left-sided colitis), it is difficult to distinguish increased clearance due to disease extent versus due to persistent inflammation at the end of induction, either of which can result in a “leaky” gut and higher clearance.

The maximum reduction in clearance with time was 26% with an onset half-life of 4.8 weeks, with onset initiation after the second dose administered (i.e., clearance constant before). The time-dependent clearance may reflect patients’ improvement in the disease over time. Generally, with less inflammation, albumin levels increase, and the change in albumin levels therefore serve as a marker of disease status. In the current model, only baseline values of albumin and CRP were assessed, as a result, time may be viewed as an indirect measure of changes in albumin over time. Models with time-varying covariates (i.e., albumin and/or CRP), instead of an empirical model, were also explored, but they were not able to fully describe the extent of CL change over time. Potential explanations for not identifying the time-varying covariates as predictors of time-varying CL may include: (1) the time-varying covariate data (CRP and albumin) reflecting the inflammation level cannot fully explain the overall changes in PK over time, and/or (2) the time-varying covariate data were sparsely sampled compared with the PK data sampling, which limits their ability to capture the PK changes over time. One explanation for the time-dependent changes may be a reduced leakiness of the gut, related to improvement in the disease, which may lead to a lower elimination of albumin and etrolizumab via feces as hypothesized for infliximab.32 An alternative or additional suggested mechanism behind the inverse relationship between clearance and albumin is that albumin, just as IgG monoclonal antibodies, interacts with (bind to) the neonatal Fc receptor, which is of importance for the protection against elimination of monoclonal antibodies via internalization, leading to the long half-life of albumin and IgG monoclonal antibodies. Therefore, in the more severe disease status, the low albumin levels could reflect a lower number of neonatal Fc receptors, leading to less internalization and then an increase in etrolizumab clearance.33

In summary, the final population PK model adequately characterized the PK properties of etrolizumab in patients with moderately-to-severely active UC and identified influential covariate effects. The final model was a two-compartment model with first-order absorption, and CL decreasing with time according to an exponential function, stepping down after each subsequent dose. The identified covariate relationships were, in general, anticipated: volumes and clearances increased with increasing body weight. CL decreased with increasing albumin or decreasing CRP, and CL was higher in patients that had been on prior TNF inhibitors and was higher in patients with extensive disease/pancolitis and other extension (vs. left-sided colitis). Model diagnostics for the final population PK model exhibited satisfactory predictive performance for etrolizumab. The external evaluation based on data from GARDENIA provided further reassurance, as the final population PK model described GARDENIA data reasonably well, which supports the model usability to derive individual predictions of etrolizumab exposure for exposure-response analysis.

AUTHOR CONTRIBUTIONS
A.M., R. Zhu, S.J., and J.R. wrote the manuscript. R. Zhu, A.M., W.Z., M.T.T., Y.S.O., T.L., R.B., N.K., and G.S. designed the research. S.J., J.R., A.M., and R. Zhu performed the research. S.J., A.M., and R. Zhang analyzed the data.

ACKNOWLEDGEMENTS
The authors thank the patients and their families who participated in these studies, and physicians and staff who conducted and/or managed these studies. Editorial assistance was provided by Anshin Biosolutions (Santa Clara, CA).

FUNDING INFORMATION
This work was supported by Genentech Inc., a member of the Roche group.

CONFLICT OF INTEREST
A.M., T.L., N.K., W.Z., G.S., R. Zhang, R.B., and R. Zhu are Genentech employees and Roche shareholders. M.T. and Y.S.O. were employees of Genentech and Roche shareholders at the time of this work. S.J. and J.R. are Pharmeretheus AB employees working under contract with Genentech.

ORCID
Tong Lu https://orcid.org/0000-0001-5899-6857
Siv Jönsson https://orcid.org/0000-0001-8240-0865
Nastya Kassir https://orcid.org/0000-0001-6193-2993
Meina Tang https://orcid.org/0000-0002-4787-742X
Rene Bruno https://orcid.org/0000-0003-0200-039X
REFERENCES

1. Brown C, Gibson PR, Hart A, et al. Long-term outcomes of colectomy surgery among patients with ulcerative colitis. *Springerplus*. 2015;4:573. doi:10.1186/s40064-015-1350-7

2. Collaborators GBDIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. *Lancet Gastroenterol Hepatol*. 2020;5:17-30. doi:10.1016/S2468-1253(19)30333-4

3. Danese S, Allez M, van Bodegraven AA, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. *Dig Dis*. 2019;37:266-283. doi:10.1159/000496739

4. Muller KR, Prosser R, Bampton P, Mountfield R, Andrews JM. Female gender and surgery impair relationships, body image, and sexuality in inflammatory bowel disease: patient perceptions. *Inflamm Bowel Dis*. 2010;16:657-663. doi:10.1002/ibd.20190

5. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. Ulcerative colitis. *Lancet*. 2017;389:1756-1770. doi:10.1016/S0140-6736(16)32126-2

6. McLean IP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. *Expert Rev Gastroenterol Hepatol*. 2014;8:223-240. doi:10.1586/17474124.2014.881715

7. Papamichael K, Rivals-Lerebours O, Billiet T, et al. Long-term outcomes of patients with ulcerative colitis and primary non-response to infliximab. *J Crohns Colitis*. 2016;10:1015-1023. doi:10.1093/jcc/jjv067

8. Cepek KL, Parker CM, Madara JL, Brenner MB. Integrin alpha E beta 7 mediates adhesion of T lymphocytes to epithelial cells. *J Immunol*. 1993;150:3459-3470.

9. Holzmann B, McIntyre BW, Weissman IL. Identification of a mucosal Peyer’s patch–specific lymphocyte homing receptor as an integrin molecule with an alpha chain homologous to human VLA-4 alpha. *Cell*. 1989;56:37-46. doi:10.1016/0092-8674(89)90981-1

10. Hu MC, Crowe DT, Weissman IL, Holzmann B. Cloning and expression of mouse integrin beta p(beta 7): a functional role in Peyer’s patch–specific lymphocyte homing. *Proc Natl Acad Sci USA*. 1992;89:8254-8258. doi:10.1073/pnas.89.17.8254

11. Danese S, Colombel JF, Lukas M, et al. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study. *Lancet Gastroenterol Hepatol*. 2022;7:118-127. doi:10.1016/S2468-1253(21)00294-6

12. Peyrin-Biroulet L, Hart A, Bossuyt P, et al. Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial. *Lancet Gastroenterol Hepatol*. 2022;7:128-140. doi:10.1016/S2468-1253(21)00298-3

13. Rubin DT, Dotan I, DuVall A, et al. Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials. *Lancet Gastroenterol Hepatol*. 2022;7:17-27. doi:10.1016/S2468-1253(21)00338-1

14. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase 1 study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. *Gut*. 2013;62:1122-1130. doi:10.1136/gutjnl-2011-301769

15. Sandborn WJ, Vermeire S, Tyrell H, et al. Etrolizumab for the treatment of ulcerative colitis and crohn’s disease: an overview of the phase 3 clinical program. *Adv Ther*. 2020;37:3417-3431. doi:10.1007/s12325-020-01366-2

16. Vermeire S, Lakatos PL, Ritter T, et al. Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study. *Lancet Gastroenterol Hepatol*. 2022;7:28-37. doi:10.1016/S2468-1253(21)00295-8

17. Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. *Lancet*. 2014;384:309-318. doi:10.1016/S0140-6736(14)60661-9

18. Kassir N, Zhu R, Moein A, et al. Exposure–response relationships of etrolizumab in patients with moderately-to-severely active ulcerative colitis. Twelfth American Conference on Pharmacometrics (ACoP12), 2021.

19. Williams K, Erickson R, Fischer SK. Overcoming disease-specific matrix effect in a clinical pharmacokinetic assay using a microfluidic immunoassay technology. *Bioanalysis*. 2017;9:1207-1216. doi:10.4155/bio-2017-0102

20. Beal S, Boeckmann L, Bauer R, Shiner L. NONMEM User’s Guide (1989–2009). Icon Development Solutions; 2009.

21. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. *Eur J Pediatr*. 2006;165:741-746. doi:10.1007/s00431-006-0188-y

22. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: modelling covariate effects. *Eur J Pediatr*. 2006;165:819-829. doi:10.1007/s00431-006-0189-x

23. Jonsson E, Harling K. Increasing the Efficiency of the Covariate Search Algorithm in the SCM (abstract). Population Approach Group Europe (PAGE); 2018.

24. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. *AAPS J.* 2011;13:143-151. doi:10.1208/s12248-011-9255-z

25. Karlsson M, Holford NA. Tutorial on Visual Predictive Checks (Abstract 1434). Population Approach Group Europe(PAGE); 2008.

26. Berends SE, Strik AS, Lowenberg M, D’Haens GR, Mathot RAA. Clinical pharmacokinetic and pharmacodynamic considerations in the treatment of ulcerative colitis. *Clin Pharmacokinet*. 2019;58:15-37. doi:10.1007/s40262-018-0676-z

27. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. *Clin Pharmacokinet*. 2010;49:633-659. doi:10.2165/11353560-000000000-00000

28. Rosario M, Dirks NL, Gastonguay MR, et al. Population pharmacokinetics–pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. *Aliment Pharmacol Ther*. 2015;42:188-202. doi:10.1111/apt.13243

29. Kevans D, Murthy S, Mould DR, Silverberg MS. Accelerated clearance of infliximab is associated with treatment failure in patients with corticosteroid-refractory acute ulcerative colitis. *J Crohns Colitis*. 2018;12:662-669. doi:10.1093/ecco-jcc/jjy028

30. Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. *CPT Pharmacometrics Syst Pharmacol*. 2017;6:576-588. doi:10.1002/psp4.12224

31. Rosario M, Dirks NL, Milich C, et al. A review of the clinical pharmacokinetics, pharmacodynamics, and immunogenicity of vedolizumab. *Clin Pharmacokinet*. 2017;56:1287-1301. doi:10.1007/s40262-017-0546-0

32. Brandse JF, van den Brink GR, Wildenberg ME, et al. Loss of infliximab into feces is associated with lack of response to therapy.
in patients with severe ulcerative colitis. *Gastroenterology*. 2015;149:350-355 e352. doi:10.1053/j.gastro.2015.04.016

33. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. *Int J Clin Pharmacol Ther*. 2010;48:297-308. doi:10.5414/cpp48297

**SUPPORTING INFORMATION**

Additional supporting information can be found online in the Supporting Information section at the end of this article.

**How to cite this article:** Moein A, Lu T, Jönsson S, et al. Population pharmacokinetic analysis of etrolizumab in patients with moderately-to-severely active ulcerative colitis. *CPT Pharmacometrics Syst Pharmacol*. 2022;11:1244-1255. doi: [10.1002/psp4.12846](https://doi.org/10.1002/psp4.12846)